Scientists at Roswell Park Cancer Institute (RPCI) have made headway in the effort to overcome resistance to treatment, publishing findings about a novel cancer drug that has been shown to inhibit several genes associated with the ability of cancer cells to survive and reproduce. A team in RPCI’s Department of Pharmacology and Therapeutics assessed the antitumor effects of FL118, a camptothecin analog that is structurally similar to irinotecan and topotecan, in preclinical studies. Read more here.
Study mentioned: Ling X, et al. A Novel Small Molecule FL118 That Selectively Inhibits Survivin, Mcl-1, XIAP and cIAP2 in a p53-Independent Manner, Shows Superior Antitumor Activity. PLoS ONE 7(9): e45571.
No comments:
Post a Comment